Skip to main content
Top
Published in: BMC Public Health 1/2011

Open Access 01-12-2011 | Study protocol

Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care

Authors: Isabel Del-Cura González, Francisca García-de-Blas González, Teresa Sanz Cuesta, Jesús Martín Fernández, Justo M Del-Alamo Rodríguez, Rosa A Escriva Ferrairo, M del Canto De-Hoyos Alonso, Laura Balsalobre Arenas, Ricardo Rodríguez Barrientos, Elisa Ceresuela Wiesmann, Cristina De-Alba Romero, Yolanda Ginés Díaz, Ana Pastor Rodríguez-Moñino, Blanca Gutiérrez Teira, Marta Sánchez-Celaya del Pozo, Jesús Fernández Horcajuelo, María J Rojas Giraldo, Paulino Cubero González, Rocío A Vello Cuadrado, Beatriz López Uriarte, Jeannet Sánchez Yepes, Yolanda Hernando Sanz, M José Iglesias Piñeiro, Susana Tudanca Hernández, Fernando Gallardo Alonso, Ana I González González, Alicia Simón Fernández, Carmen Carballo, Ana Rey López, Fernanda Morales, Dolores Martínez López, GRUPO PRESEVAC

Published in: BMC Public Health | Issue 1/2011

Login to get access

Abstract

Background

Vaginitis is a common complaint in primary care. In uncomplicated candidal vaginitis, there are no differences in effectiveness between oral or vaginal treatment. Some studies describe that the preferred treatment is the oral one, but a Cochrane's review points out inconsistencies associated with the report of the preferred way that limit the use of such data. Risk factors associated with recurrent vulvovaginal candidiasis still remain controversial.

Methods/Design

This work describes a protocol of a multicentric prospective observational study with one year follow up, to describe the women's reasons and preferences to choose the way of administration (oral vs topical) in the treatment of not complicated candidal vaginitis. The number of women required is 765, they are chosen by consecutive sampling. All of whom are aged 16 and over with vaginal discharge and/or vaginal pruritus, diagnosed with not complicated vulvovaginitis in Primary Care in Madrid.
The main outcome variable is the preferences of the patients in treatment choice; secondary outcome variables are time to symptoms relief and adverse reactions and the frequency of recurrent vulvovaginitis and the risk factors. In the statistical analysis, for the main objective will be descriptive for each of the variables, bivariant analysis and multivariate analysis (logistic regression).. The dependent variable being the type of treatment chosen (oral or topical) and the independent, the variables that after bivariant analysis, have been associated to the treatment preference.

Discussion

Clinical decisions, recommendations, and practice guidelines must not only attend to the best available evidence, but also to the values and preferences of the informed patient.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sociedad Española de Medicina de Familia y Comunitaria: Guía de actuación en atención primaria: Barcelona. 2007 Sociedad Española de Medicina de Familia y Comunitaria: Guía de actuación en atención primaria: Barcelona. 2007
2.
3.
go back to reference Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK: Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998, 92 (5): 757-765.PubMed Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK: Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998, 92 (5): 757-765.PubMed
4.
go back to reference Rodgers CA, Beardall AJ: Recurrent vulvovaginal candidiasis: why does it occur?. Int.J.STD AIDS. 1999, 10 (7): 435-9. quiz 440-1CrossRefPubMed Rodgers CA, Beardall AJ: Recurrent vulvovaginal candidiasis: why does it occur?. Int.J.STD AIDS. 1999, 10 (7): 435-9. quiz 440-1CrossRefPubMed
5.
go back to reference Egan ME, Lipsky MS: Diagnosis of vaginitis. Am Fam Physician. 2000, 62 (5): 1095-1104.PubMed Egan ME, Lipsky MS: Diagnosis of vaginitis. Am Fam Physician. 2000, 62 (5): 1095-1104.PubMed
7.
go back to reference Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998, 178 (2): 203-211.CrossRefPubMed Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998, 178 (2): 203-211.CrossRefPubMed
8.
go back to reference Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A: Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2007, 4: CD002845-PubMed Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A: Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2007, 4: CD002845-PubMed
9.
go back to reference Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48 (5): 503-535.CrossRefPubMed Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48 (5): 503-535.CrossRefPubMed
10.
go back to reference Adetoro OO: Comparative trial of a single oral dose of fluconazole (150 mg) and a single intravaginal tablet of clotrimazole (500 mg) in the treatment of vaginal candidiasis. Curr Ther Res Clin Exp. 1990, 48 (2): 275-281. Adetoro OO: Comparative trial of a single oral dose of fluconazole (150 mg) and a single intravaginal tablet of clotrimazole (500 mg) in the treatment of vaginal candidiasis. Curr Ther Res Clin Exp. 1990, 48 (2): 275-281.
11.
go back to reference A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Report of an international multicentre trial. Br J Obstet Gynaecol. 1989, 96 (2): 226-232. A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Report of an international multicentre trial. Br J Obstet Gynaecol. 1989, 96 (2): 226-232.
12.
go back to reference Osser S, Haglund A, Westrom L: Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. Acta Obstet Gynecol Scand. 1991, 70 (1): 73-78.CrossRefPubMed Osser S, Haglund A, Westrom L: Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. Acta Obstet Gynecol Scand. 1991, 70 (1): 73-78.CrossRefPubMed
13.
go back to reference Slavin MB, Benrubi GI, Parker R, Griffin CR, Magee MJ: Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study. J Fla Med Assoc. 1992, 79 (10): 693-696.PubMed Slavin MB, Benrubi GI, Parker R, Griffin CR, Magee MJ: Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study. J Fla Med Assoc. 1992, 79 (10): 693-696.PubMed
14.
go back to reference Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, et al: Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group Am J Obstet Gynecol. 1995, 172 (4 Pt 1): 1263-1268.CrossRef Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, et al: Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group Am J Obstet Gynecol. 1995, 172 (4 Pt 1): 1263-1268.CrossRef
15.
go back to reference Timonen H, Hartikainen-Vahtera P, Kivijarvi A, Kohtamaki K, Kosunen M, Lehtonen L, et al: A doube-blind comparison of the effectiveness of itraconazole oral capsules with econazole vaginal capsules in the treatment of vaginal candidosis. Drug Invest. 1992, 4 (6): 515-520.CrossRef Timonen H, Hartikainen-Vahtera P, Kivijarvi A, Kohtamaki K, Kosunen M, Lehtonen L, et al: A doube-blind comparison of the effectiveness of itraconazole oral capsules with econazole vaginal capsules in the treatment of vaginal candidosis. Drug Invest. 1992, 4 (6): 515-520.CrossRef
16.
go back to reference Timonen H: Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole. Mycoses. 1992, 35 (11-12): 317-320.CrossRefPubMed Timonen H: Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole. Mycoses. 1992, 35 (11-12): 317-320.CrossRefPubMed
17.
go back to reference Stein GE, Mummaw N: Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother. 1993, 37 (1): 89-92.CrossRefPubMedPubMedCentral Stein GE, Mummaw N: Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother. 1993, 37 (1): 89-92.CrossRefPubMedPubMedCentral
18.
go back to reference Tobin JM, Loo P, Granger SE: Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourin Med. 1992, 68 (1): 36-38.PubMedPubMedCentral Tobin JM, Loo P, Granger SE: Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourin Med. 1992, 68 (1): 36-38.PubMedPubMedCentral
19.
go back to reference van Heusden AM, Merkus HM, Euser R, Verhoeff A: A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists. Eur J Obstet Gynecol Reprod Biol. 1994, 55 (2): 123-127.CrossRefPubMed van Heusden AM, Merkus HM, Euser R, Verhoeff A: A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists. Eur J Obstet Gynecol Reprod Biol. 1994, 55 (2): 123-127.CrossRefPubMed
20.
go back to reference van Heusden AM, Merkus HM, Corbeij RS, Oosterbaan HP, Stoot JE, Ubachs HM, et al: Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. Acta Obstet Gynecol Scand. 1990, 69 (5): 417-422.CrossRefPubMed van Heusden AM, Merkus HM, Corbeij RS, Oosterbaan HP, Stoot JE, Ubachs HM, et al: Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. Acta Obstet Gynecol Scand. 1990, 69 (5): 417-422.CrossRefPubMed
21.
go back to reference das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, et al: Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs. 2008, 68 (13): 1787-1802.CrossRefPubMed das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, et al: Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs. 2008, 68 (13): 1787-1802.CrossRefPubMed
22.
23.
go back to reference Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S: Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol. 1993, 81 (5 (Pt 1)): 721-727.PubMed Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S: Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol. 1993, 81 (5 (Pt 1)): 721-727.PubMed
24.
go back to reference Fosch S, Fogolin N, Azzaroni E, Pairetti N, Dana L, Minacori H, et al: Vulvovaginitis: correlation with predisposing factors, clinical manifestations and microbiological studies. Rev Argent Microbiol. 2006, 38 (4): 202-205.PubMed Fosch S, Fogolin N, Azzaroni E, Pairetti N, Dana L, Minacori H, et al: Vulvovaginitis: correlation with predisposing factors, clinical manifestations and microbiological studies. Rev Argent Microbiol. 2006, 38 (4): 202-205.PubMed
25.
26.
go back to reference Evidence-Based Medicine Working Group: Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992, 268 (17): 2420-2425.CrossRef Evidence-Based Medicine Working Group: Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992, 268 (17): 2420-2425.CrossRef
30.
go back to reference van Wersch A, Eccles M: Involvement of consumers in the development of evidence based clinical guidelines: practical experiences from the North of England evidence based guideline development programme. Qual Health Care. 2001, 10 (1): 10-16.CrossRefPubMedPubMedCentral van Wersch A, Eccles M: Involvement of consumers in the development of evidence based clinical guidelines: practical experiences from the North of England evidence based guideline development programme. Qual Health Care. 2001, 10 (1): 10-16.CrossRefPubMedPubMedCentral
31.
go back to reference Pinto J, Abellán J, Sánchez F: Incorporación de las preferencias de los pacientes en la toma de decisiones clínicas. 2004, Barcelona: Masson S.A., 1 Pinto J, Abellán J, Sánchez F: Incorporación de las preferencias de los pacientes en la toma de decisiones clínicas. 2004, Barcelona: Masson S.A., 1
32.
go back to reference Martin-Fernandez J, Gomez-Gascon T, Oliva-Moreno J, del Cura-Gonzalez MI, Dominguez-Bidagor J, Beamud-Lagos M, et al: Perception of the economic value of primary care services: a Willingness to Pay study. Health Policy. 2010, 94 (3): 266-272.CrossRefPubMed Martin-Fernandez J, Gomez-Gascon T, Oliva-Moreno J, del Cura-Gonzalez MI, Dominguez-Bidagor J, Beamud-Lagos M, et al: Perception of the economic value of primary care services: a Willingness to Pay study. Health Policy. 2010, 94 (3): 266-272.CrossRefPubMed
33.
go back to reference Garcia de Blas Gonzalez F, Barajas Gutierrez MA, Beneyto Martin P, Del Cura Gonzalez MI, Sanz Cuesta T, Vello Cuadrado R, et al: Usefulness of a glaucoma and ocular hypertension screening strategy in primary care. Aten Primaria. 2007, 39 (4): 181-184.CrossRefPubMed Garcia de Blas Gonzalez F, Barajas Gutierrez MA, Beneyto Martin P, Del Cura Gonzalez MI, Sanz Cuesta T, Vello Cuadrado R, et al: Usefulness of a glaucoma and ocular hypertension screening strategy in primary care. Aten Primaria. 2007, 39 (4): 181-184.CrossRefPubMed
34.
go back to reference Calderón Gómez C: ¿Se puede integrar la evidencia procedente de la investigación cualitativa y la cuantitativa?. FMC. 2004, 11 (3): 157-178. Calderón Gómez C: ¿Se puede integrar la evidencia procedente de la investigación cualitativa y la cuantitativa?. FMC. 2004, 11 (3): 157-178.
35.
go back to reference Bingham JS: Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br J Vener Dis. 1984, 60 (3): 175-177.PubMedPubMedCentral Bingham JS: Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br J Vener Dis. 1984, 60 (3): 175-177.PubMedPubMedCentral
36.
go back to reference Stein GE, Christensen S, Mummaw N: Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP. 1991, 25 (6): 582-585.PubMed Stein GE, Christensen S, Mummaw N: Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP. 1991, 25 (6): 582-585.PubMed
37.
go back to reference Seidman LS, Skokos CK: An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. Infect Dis Obstet Gynecol. 2005, 13 (4): 197-206.CrossRefPubMedPubMedCentral Seidman LS, Skokos CK: An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. Infect Dis Obstet Gynecol. 2005, 13 (4): 197-206.CrossRefPubMedPubMedCentral
Metadata
Title
Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care
Authors
Isabel Del-Cura González
Francisca García-de-Blas González
Teresa Sanz Cuesta
Jesús Martín Fernández
Justo M Del-Alamo Rodríguez
Rosa A Escriva Ferrairo
M del Canto De-Hoyos Alonso
Laura Balsalobre Arenas
Ricardo Rodríguez Barrientos
Elisa Ceresuela Wiesmann
Cristina De-Alba Romero
Yolanda Ginés Díaz
Ana Pastor Rodríguez-Moñino
Blanca Gutiérrez Teira
Marta Sánchez-Celaya del Pozo
Jesús Fernández Horcajuelo
María J Rojas Giraldo
Paulino Cubero González
Rocío A Vello Cuadrado
Beatriz López Uriarte
Jeannet Sánchez Yepes
Yolanda Hernando Sanz
M José Iglesias Piñeiro
Susana Tudanca Hernández
Fernando Gallardo Alonso
Ana I González González
Alicia Simón Fernández
Carmen Carballo
Ana Rey López
Fernanda Morales
Dolores Martínez López
GRUPO PRESEVAC
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2011
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-11-63

Other articles of this Issue 1/2011

BMC Public Health 1/2011 Go to the issue